BEVYXXA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BEVYXXA (BEVYXXA).
Factor Xa inhibitor; selectively and reversibly inhibits the active site of factor Xa, thereby converting prothrombin to thrombin, which ultimately reduces thrombus formation.
| Metabolism | Primarily hydrolyzed by amidases (esterases) to active metabolite (M1); minor CYP3A4/5 and CYP2J2 involvement; M1 further metabolized via CYP3A4/5 and CYP2J2. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 50% of the administered dose; fecal/biliary elimination accounts for about 30% as metabolites; the remainder is eliminated via other pathways. |
| Half-life | Terminal elimination half-life is approximately 12-15 hours in healthy volunteers; may be prolonged in patients with renal impairment, requiring dose adjustment for CrCl <30 mL/min. |
| Protein binding | Approximately 60-70% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 0.8-1.2 L/kg, suggesting distribution into total body water with moderate tissue binding. |
| Bioavailability | Oral bioavailability is approximately 80% under fasted conditions; food may delay absorption but does not significantly affect total exposure. |
| Onset of Action | Oral administration: Onset of antithrombotic effect occurs within 2-4 hours post-dose. |
| Duration of Action | The antithrombotic effect persists for 12-24 hours after a single dose; clinical anticoagulation monitoring is not routinely required, but effect wanes after 24 hours. |
Oral, 5 mg twice daily.
| Dosage form | CAPSULE |
| Renal impairment | Contraindicated in patients with GFR < 15 mL/min. No dose adjustment required for GFR ≥ 15 mL/min. |
| Liver impairment | Contraindicated in Child-Pugh Class C. No dose adjustment for Child-Pugh A or B. |
| Pediatric use | Not established; safety and efficacy in pediatric patients have not been studied. |
| Geriatric use | No dose adjustment required based on age alone; consider renal function and comorbidity status. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BEVYXXA (BEVYXXA).
| Breastfeeding | No human data; M/P ratio unknown. Drug excreted in rat milk. Due to potential for bleeding in nursing infant, discontinue breastfeeding or discontinue drug. Use not recommended. |
| Teratogenic Risk | BEVYXXA (factor Xa inhibitor) is contraindicated in pregnancy due to teratogenicity observed in animal studies. First trimester: increased risk of spontaneous abortion and major malformations (neural tube, cardiac). Second/third trimester: fetal hemorrhage, placental abruption, preterm birth. Not approved for use in pregnancy. |
■ FDA Black Box Warning
Epidural or spinal hematomas may occur in patients treated with anticoagulants, including BEVYXXA, who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks before scheduling neuraxial procedures.
| Serious Effects |
Active pathological bleeding; severe hypersensitivity to betrixaban or any excipient; concomitant use with strong P-glycoprotein (P-gp) inhibitors (e.g., ketoconazole, itraconazole, ritonavir) in patients with severe renal impairment (CrCl <30 mL/min); patients with prosthetic heart valves.
| Precautions | Increased risk of bleeding; spinal/epidural hematomas with neuraxial anesthesia; acute renal failure; elevated liver enzymes; premature discontinuation increases thrombotic risk; prosthetic heart valves not studied. |
| Food/Dietary | Take with food to increase bioavailability. Avoid grapefruit juice as it may alter drug levels (theoretical interaction based on CYP3A4 metabolism; however, betrixaban is not extensively metabolized by CYP3A4, but caution advised). No other specific dietary restrictions. |
Loading safety data…
| Fetal Monitoring |
| Monitor for signs of bleeding (gums, bruising, epistaxis, hematuria). If inadvertent exposure in pregnancy, perform fetal ultrasound for structural anomalies and assess for hemorrhage. Monitor maternal coagulation parameters (anti-Xa activity) if needed. |
| Fertility Effects | No human fertility studies. Animal studies show no impairment of male or female fertility. However, anticoagulant therapy may increase risk of hemorrhagic ovarian cysts, potentially affecting ovulation. |
| Clinical Pearls | Bevyxxa (betrixaban) is a factor Xa inhibitor approved for extended venous thromboembolism (VTE) prophylaxis in acutely ill medical patients. Avoid use in patients with severe renal impairment (CrCl <15 mL/min) or on dual antiplatelet therapy. No routine coagulation monitoring required. Administer with food to enhance absorption. Discontinue at least 72 hours prior to surgical interventions with high bleeding risk. |
| Patient Advice | Take exactly as prescribed; do not skip doses or stop without consulting your doctor. · Take with food to ensure proper absorption. · Report any signs of bleeding (unusual bruising, red or black stools, coughing up blood, prolonged bleeding from cuts) or symptoms of spinal hematoma (back pain, numbness, weakness) if you have received spinal puncture or anesthesia. · Inform all healthcare providers that you are taking Bevyxaa before any surgery or dental procedure. · Do not take with other blood thinners unless specifically directed by your doctor. · Store at room temperature, away from moisture and heat. · If a dose is missed, take it as soon as remembered on the same day; do not double dose the next day. |